邱夫斯基
Lv4
690 积分
2023-12-20 加入
-
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
19天前
已完结
-
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
24天前
已完结
-
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
2个月前
已完结
-
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
2个月前
已完结
-
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
2个月前
已完结
-
Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg (STEP 8)
2个月前
已完结
-
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
4个月前
已关闭
-
Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese
4个月前
已关闭
-
Efficacy and safety of semaglutide 2.4 mg once- weekly in adults with overweight or obesity and type 2 diabetes (STEP 2)
4个月前
已关闭
-
Once-Weekly Semaglutide Is an Effective Adjunct for Weight Loss in Adults without Diabetes Who Are Overweight or Obese
4个月前
已关闭